ExceptGen, a San Francisco, CA-based genetic medicine startup, raised $4M in funding.
The round, which brought the total amount to $14M, was led by RA Capital Management and backed by Gravity Fund, Apollo Projects (Sam Altman), and other investors.
The company intends to use the funds to accelerate its research and development efforts, as well as advance its collaborations with other companies.
Led by CEO Thomas Folliard and Barbara Mertins, ExcepGen is a genetic medicine startup that emerged from stealth advancing its technology to make nucleic acid therapeutics more powerful. It works by encoding a specialized “shield” protein alongside the main nucleic acid cargo, which improves how cells react to the foreign DNA or RNA and prevents negative cell signaling. By this mechanism, its technology could massively expand the reach of both DNA-based and RNA-based genetic medicines by enhancing their effectiveness and tolerability.
FinSMEs
24/08/2023